|
David Buckeridge Person1 #679775 David is a Professor in the School of Population and Global Health at McGill University, where he directs the Surveillance Lab, an interdisciplinary group that develops, implements, and evaluates novel computational methods for population health surveillance. He is also the Chief Digital Health Officer at the McGill University Health Center where he directs strategy on digital transformation and analytics and he is an Associate Member with the Montreal Institute for Learning Algorithms (Mila). | - His research and practice focus on the informatics of health surveillance and disease control and he holds a Canada Research Chair (Tier 1) in Health Informatics and Data Science. In the context of the COVID-19 pandemic, Dr Buckeridge provides regular projections of health system demand for the Canadian province of Quebec, is the Scientific lead for Data Management and Analytics for the Canadian Immunity Task Force, and is funded by the World Health Organization (WHO) to monitor global immunity to SARS-CoV-2. He is also a technical advisor to the WHO Epidemic Intelligence from Open Sources (EIOS) program on the application of artificial intelligence to global infectious disease surveillance. Dr Buckeridge has a MD from Queen's University, a MSc in Epidemiology from the University of Toronto, a PhD in Biomedical informatics from Stanford University, and is a Fellow of the Royal College of Physicians of Canada.
|
+Citations (8) - CitationsAdd new citationList by: CiterankMapLink[3] Applied artificial intelligence in healthcare: Listening to the winds of change in a post-COVID-19 world
Author: Arash Shaban-Nejad, Martin Michalowski, Robert L Davis, et al. Publication date: 25 November 2022 Publication info: Experimental Biology and Medicine, Volume 247, Issue 22 Cited by: David Price 9:04 PM 26 November 2023 GMT Citerank: (2) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704019Artificial intelligence859FDEF6 URL: DOI: https://doi.org/10.1177/1535370222114040
| Excerpt / Summary [Experimental Biology and Medicine, 25 November 2022]
This editorial article aims to highlight advances in artificial intelligence (AI) technologies in five areas: Collaborative AI, Multimodal AI, Human-Centered AI, Equitable AI, and Ethical and Value-based AI in order to cope with future complex socioeconomic and public health issues. |
Link[4] Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Author: Isabel Bergeri, Mairead G. Whelan, Harriet Ware, et al. Unity Studies Collaborator Group - Lorenzo Subissi, Anthony Nardone, Hannah C. Lewis, Zihan Li,Xiaomeng Ma, Marta Valenciano, Brianna Cheng, Lubna Al Ariqi, Arash Rashidian, Joseph Okeibunor, Tasnim Azim, Pushpa Wijesinghe, Linh-Vi Le, Aisling Vaughan, Richard Pebody, Andrea Vicari, Tingting Yan, Mercedes Yanes-Lane, Christian Cao, David A. Clifton, Matthew P. Cheng, Jesse Papenburg, David Buckeridge, Niklas Bobrovitz, Rahul K. Arora, Maria D. Van Kerkhove Publication date: 10 November 2022 Publication info: PLoS Med 19(11): e1004107 Cited by: David Price 9:12 PM 26 November 2023 GMT Citerank: (3) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704045Covid-19859FDEF6, 715376Serosurveillance859FDEF6 URL: DOI: https://doi.org/10.1371/journal.pmed.1004107
| Excerpt / Summary [PLoS Medicine, 10 November 2022]
Background: Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic.
Methods and findings: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented.
Conclusions: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions. |
Link[5] Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance
Author: Claire Donnici, Natasha Ilincic, Christian Cao, Caseng Zhang, Gabriel Deveaux, David Clifton, David Buckeridge, Niklas Bobrovitz, Rahul K. Arora Publication date: 26 October 2022 Publication info: Epidemics, Volume 41, 2022, 100645, ISSN 1755-4365 Cited by: David Price 10:30 PM 27 November 2023 GMT Citerank: (3) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704045Covid-19859FDEF6, 715376Serosurveillance859FDEF6 URL: DOI: https://doi.org/10.1016/j.epidem.2022.100645
| Excerpt / Summary [Epidemics, 26 October 2022]
Seroprevalence studies have been used throughout the COVID-19 pandemic to monitor infection and immunity. These studies are often reported in peer-reviewed journals, but the academic writing and publishing process can delay reporting and thereby public health action. Seroprevalence estimates have been reported faster in preprints and media, but with concerns about data quality. We aimed to (i) describe the timeliness of SARS-CoV-2 serosurveillance reporting by publication venue and study characteristics and (ii) identify relationships between timeliness, data validity, and representativeness to guide recommendations for serosurveillance efforts. We included seroprevalence studies published between January 1, 2020 and December 31, 2021 from the ongoing SeroTracker living systematic review. For each study, we calculated timeliness as the time elapsed between the end of sampling and the first public report. We evaluated data validity based on serological test performance and correction for sampling error, and representativeness based on the use of a representative sample frame and adequate sample coverage. We examined how timeliness varied with study characteristics, representativeness, and data validity using univariate and multivariate Cox regression. We analyzed 1844 studies. Median time to publication was 154 days (IQR 64–255), varying by publication venue (journal articles: 212 days, preprints: 101 days, institutional reports: 18 days, and media: 12 days). Multivariate analysis confirmed the relationship between timeliness and publication venue and showed that general population studies were published faster than special population or health care worker studies; there was no relationship between timeliness and study geographic scope, geographic region, representativeness, or serological test performance. Seroprevalence studies in peer-reviewed articles and preprints are published slowly, highlighting the limitations of using the academic literature to report seroprevalence during a health crisis. More timely reporting of seroprevalence estimates can improve their usefulness for surveillance, enabling more effective responses during health emergencies. |
Link[6] The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020–2023
Author: Tanya J. Murphy, Hanna Swail, Jaspreet Jain, David L. Buckeridge, et al. - Maureen Anderson, Philip Awadalla, Lesley Behl, Patrick E. Brown, Carmen L. Charlton, Karen Colwill, Steven J. Drews, Anne-Claude Gingras, Deena Hinshaw, Prabhat Jha, Jamil N. Kanji, Victoria A. Kirsh, Amanda L.S. Lang, Marc-André Langlois, Stephen Lee, Antoine Lewin, Sheila F. O’Brien, Chantale Pambrun, Kimberly Skead, David A. Stephens, Derek R. Stein, Graham Tipples, Paul G. Van Caeseele, Timothy G. Evans, Olivia Oxlade, Bruce D. Mazer Publication date: 14 August 2023 Publication info: CMAJ August 14, 2023 195 (31) E1030-E1037 Cited by: David Price 0:32 AM 28 November 2023 GMT Citerank: (3) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704045Covid-19859FDEF6, 715376Serosurveillance859FDEF6 URL: DOI: https://doi.org/10.1503/cmaj.230249
| Excerpt / Summary [CMAJ, 14 August 2023]
Background: During the first year of the COVID-19 pandemic, the proportion of reported cases of COVID-19 among Canadians was under 6%. Although high vaccine coverage was achieved in Canada by fall 2021, the Omicron variant caused unprecedented numbers of infections, overwhelming testing capacity and making it difficult to quantify the trajectory of population immunity.
Methods: Using a time-series approach and data from more than 900 000 samples collected by 7 research studies collaborating with the COVID-19 Immunity Task Force (CITF), we estimated trends in SARS-CoV-2 seroprevalence owing to infection and vaccination for the Canadian population over 3 intervals: prevaccination (March to November 2020), vaccine roll-out (December 2020 to November 2021), and the arrival of the Omicron variant (December 2021 to March 2023). We also estimated seroprevalence by geographical region and age.
Results: By November 2021, 9.0% (95% credible interval [CrI] 7.3%–11%) of people in Canada had humoral immunity to SARS-CoV-2 from an infection. Seroprevalence increased rapidly after the arrival of the Omicron variant — by Mar. 15, 2023, 76% (95% CrI 74%–79%) of the population had detectable antibodies from infections. The rapid rise in infection-induced antibodies occurred across Canada and was most pronounced in younger age groups and in the Western provinces: Manitoba, Saskatchewan, Alberta and British Columbia.
Interpretation: Data up to March 2023 indicate that most people in Canada had acquired antibodies against SARS-CoV-2 through natural infection and vaccination. However, given variations in population seropositivity by age and geography, the potential for waning antibody levels, and new variants that may escape immunity, public health policy and clinical decisions should be tailored to local patterns of population immunity.
The COVID-19 pandemic defied expectations about immunity arising from infection and vaccination. During the first months of the pandemic, despite the burden on Canadian society and health systems, rates of symptomatic infection remained low, with 580 000 confirmed cases by December 2020, representing 1.6% of the Canadian population.1 Vaccines were widely distributed in Canada beginning in early 2021, with a rapid rise in vaccine coverage to 79% by fall of 2021,2 whereas cumulative reported cases of COVID-19 remained low, at 4.7% of the population.3 The arrival of Omicron variants and subvariants, however, caused an unprecedented increase in the number of infections. In short, the high vaccine coverage, combined with population immunity from infections in earlier waves of the pandemic, were insufficient to slow the spread of the Omicron variant.
Although the overall progression of confirmed cases and vaccination is clear, the underlying dynamics of population seropositivity are less obvious, yet critically important for policy and clinical decisions about vaccination and other preventive measures. A count of confirmed cases of COVID-19 is of limited use for understanding the evolution of population immunity because case ascertainment is biased by multiple factors. Most notably, access to laboratory-based polymerase chain reaction (PCR) testing varied across the country and, in many locations, was overwhelmed by demand after December 2021. In this context, serological surveillance provides an informative adjunct to monitoring confirmed cases, as seroprevalence offers a more direct measure of population humoral immunity.
We sought to describe the trajectory of SARS-CoV-2 seroprevalence in the Canadian population, as measured by anti-nucleocapsid (anti-N) and anti-spike protein (anti-S) antibody levels over 3 intervals: prevaccination (March to November 2020), vaccine roll-out (December 2020 to November 2021), and the Omicron variant waves (December 2021 to March 2023). We draw on seroprevalence estimates from multiple studies collaborating with the COVID-19 Immunity Task Force (CITF).4 In addition to describing the temporal evolution of population seropositivity in Canada, we highlight trends in infection-acquired and vaccine-induced seroprevalence by Canadian region and age.
|
Link[7] A Joint Temporal Model for Hospitalizations and ICU Admissions Due to COVID-19 in Quebec
Author: Mariana Carmona-Baez, Alexandra M. Schmidt, Shirin Golchi, David Buckeridge Publication date: 6 September 2024 Publication info: Stat, Volume 13, Issue 3 e70000, 6 September 2024 Cited by: David Price 1:21 PM 2 December 2024 GMT Citerank: (4) 685420Hospitals16289D5D4, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704045Covid-19859FDEF6, 728389Covid-19Covid-19 » Who. » David Buckeridge10000FFFACD URL: DOI: https://doi.org/10.1002/sta4.70000
| Excerpt / Summary [Stat, 6 September 2024]
Infectious respiratory diseases have been of interest in recent years for the great burden they place on health systems, for instance, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused the global COVID-19 pandemic. As many of these diseases might require hospitalization and even intensive care unit (ICU) admission, understanding the joint dynamics of hospitalizations and ICU admissions across time and different groups of the population remains of great importance. We aim to understand the joint evolution of hospital and ICU admissions given COVID-19 test-positive cases in the province of Quebec, Canada. We obtain the daily counts, by age group, on the number of confirmed COVID-19 cases, the number of hospitalizations and the number of ICU admissions due to COVID-19, from March 2020 through October 2021 in Quebec. We propose a joint Bayesian generalized dynamic linear model for the number of hospitalizations and ICU admissions to study their temporal trends and possible associations with sex and age group. Additionally, we use transfer functions to investigate if there is a memory effect of the number of cases on hospitalizations across the different age groups. The results suggest that there is a clear distinction in the patterns of hospitalizations and ICU admissions across age groups and that the number of cases has a persistent effect on the rate of hospitalization. |
Link[8] Canada’s provincial COVID-19 pandemic modelling efforts: A review of mathematical models and their impacts on the responses
Author: Yiqing Xia, Jorge Luis Flores Anato, Caroline Colijn, Naveed Janjua, Mike Irvine, Tyler Williamson, Marie B. Varughese, Michael Li, Nathaniel Osgood, David J. D. Earn, Beate Sander, Lauren E. Cipriano, Kumar Murty, Fanyu Xiu, Arnaud Godin, David Buckeridge, Amy Hurford, Sharmistha Mishra, Mathieu Maheu-Giroux Publication date: 25 July 2024 Publication info: Canadian Journal of Public Health, Volume 115, pages 541–557, (2024) Cited by: David Price 0:40 AM 10 December 2024 GMT
Citerank: (14) 679712CANMOD – PeopleCANMOD is a national network, with members located across the country and associated with a broader Emerging Infectious Disease Modelling (EIDM) initiative. We are a community of modellers, statisticians, epidemiologists, public health decision-makers, and those implementing and delivering interventions.10019D3ABAB, 679752Amy HurfordAmy Hurford is an Associate Professor jointly appointed in the Department of Biology and the Department of Mathematics and Statistics at Memorial University of Newfoundland and Labrador. 10019D3ABAB, 679757Beate SanderCanada Research Chair in Economics of Infectious Diseases and Director, Health Modeling & Health Economics and Population Health Economics Research at THETA (Toronto Health Economics and Technology Assessment Collaborative).10019D3ABAB, 679761Caroline ColijnDr. Caroline Colijn works at the interface of mathematics, evolution, infection and public health, and leads the MAGPIE research group. She joined SFU's Mathematics Department in 2018 as a Canada 150 Research Chair in Mathematics for Infection, Evolution and Public Health. She has broad interests in applications of mathematics to questions in evolution and public health, and was a founding member of Imperial College London's Centre for the Mathematics of Precision Healthcare.10019D3ABAB, 679776David EarnProfessor of Mathematics and Faculty of Science Research Chair in Mathematical Epidemiology at McMaster University.10019D3ABAB, 679844Mathieu Maheu-GirouxCanada Research Chair (Tier 2) in Population Health Modeling and Associate Professor, McGill University.10019D3ABAB, 679855Nathaniel OsgoodNathaniel D. Osgood is a Professor in the Department of Computer Science and Associate Faculty in the Department of Community Health & Epidemiology at the University of Saskatchewan.10019D3ABAB, 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 679880Sharmistha MishraSharmistha Mishra is an infectious disease physician and mathematical modeler and holds a Tier 2 Canadian Research Chair in Mathematical Modeling and Program Science.10019D3ABAB, 679893Kumar MurtyProfessor Kumar Murty is in the Department of Mathematics at the University of Toronto. His research fields are Analytic Number Theory, Algebraic Number Theory, Arithmetic Algebraic Geometry and Information Security. He is the founder of the GANITA lab, co-founder of Prata Technologies and PerfectCloud. His interest in mathematics ranges from the pure study of the subject to its applications in data and information security.10019D3ABAB, 685387Michael Y LiProfessor of Mathematics in the Department of Mathematical and Statistical Sciences at the University of Alberta, and Director of the Information Research Lab (IRL).10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 701037MfPH – Publications144B5ACA0, 704045Covid-19859FDEF6 URL: DOI: https://doi.org/10.17269/s41997-024-00910-9
| Excerpt / Summary [Canadian Journal of Public Health, 25 July 2024]
Setting: Mathematical modelling played an important role in the public health response to COVID-19 in Canada. Variability in epidemic trajectories, modelling approaches, and data infrastructure across provinces provides a unique opportunity to understand the factors that shaped modelling strategies.
Intervention: Provinces implemented stringent pandemic interventions to mitigate SARS-CoV-2 transmission, considering evidence from epidemic models. This study aimed to summarize provincial COVID-19 modelling efforts. We identified modelling teams working with provincial decision-makers, through referrals and membership in Canadian modelling networks. Information on models, data sources, and knowledge translation were abstracted using standardized instruments.
Outcomes: We obtained information from six provinces. For provinces with sustained community transmission, initial modelling efforts focused on projecting epidemic trajectories and healthcare demands, and evaluating impacts of proposed interventions. In provinces with low community transmission, models emphasized quantifying importation risks. Most of the models were compartmental and deterministic, with projection horizons of a few weeks. Models were updated regularly or replaced by new ones, adapting to changing local epidemic dynamics, pathogen characteristics, vaccines, and requests from public health. Surveillance datasets for cases, hospitalizations and deaths, and serological studies were the main data sources for model calibration. Access to data for modelling and the structure for knowledge translation differed markedly between provinces.
Implication: Provincial modelling efforts during the COVID-19 pandemic were tailored to local contexts and modulated by available resources. Strengthening Canadian modelling capacity, developing and sustaining collaborations between modellers and governments, and ensuring earlier access to linked and timely surveillance data could help improve pandemic preparedness. |
|
|